The present invention generally relates to apparatus, methods and systems for detecting the presence of one or more target analytes or specific biological materials in a sample, and more particularly to a laser compact disc system for detecting the presence of biological materials and/or analyte molecules bound to target receptors on a disc by sensing changes in the optical characteristics of a probe beam reflected, transmitted, or diffracted by the disc caused by the materials and/or analytes.
In many chemical, biological, medical, and diagnostic applications, it is desirable to detect the presence of specific molecular structures in a sample. Many molecular structures such as cells, viruses, bacteria, toxins, peptides, DNA fragments, pathogens, and antibodies are recognized by particular receptors. Biochemical technologies including gene chips, immunological chips, and DNA arrays for detecting gene expression patterns in cancer cells, exploit the interaction between these molecular structures and the receptors. [For examples see the descriptions in the following articles: Sanders, G. H. W. and A. Manz, Chip-based Microsystems for genomic and proteomic analysis. Trends in Anal. Chem., 2000, Vol. 19(6), p. 364-378. Wang, J., From DNA biosensors to gene chips. Nucl. Acids Res., 2000, Vol. 28(16), p. 3011-3016; Hagman, M., Doing immunology on a chip. Science, 2000, Vol. 290, p. 82-83; Marx, J., DNA Arrays reveal cancer in its many forms. Science, 2000, Vol. 289, p. 1670-1672]. These technologies generally employ a stationary chip prepared to include the desired receptors (those which interact with the target analyte or molecular structure under test). Since the receptor areas can be quite small, chips may be produced which test for a plurality of analytes. Ideally, many thousand binding receptors are provided to provide a complete assay. When the receptors are exposed to a biological sample, only a few may bind a specific protein or pathogen. Ideally, these receptor sites are identified in as short a time as possible.
One such technology for screening for a plurality of molecular structures is the so-called immunological compact disk, which simply includes an antibody microarray. [For examples see the descriptions in the following articles: Ekins, R., F. Chu, and E. Biggart, Development of microspot multi-analyte ratiometric immunoassay using dual flourescent-labelled antibodies. Anal. Chim. Acta, 1989, Vol. 227, p. 73-96; Ekins, R. and F. W. Chu, Multianalyte microspot immunoassay—Microanalytical “compact Disk” of the future. Clin. Chem., 1991, Vol. 37(11), p. 1955-1967; Ekins, R., Ligand assays: from electrophoresis to miniaturized microarrays. Clin. Chem., 1998, Vol. 44(9), p. 2015-2030]. Conventional fluorescence detection is employed to sense the presence in the microarray of the molecular structures under test. Other approaches to immunological assays employ traditional Mach-Zender interferometers that include waveguides and grating couplers. [For examples see the descriptions in the following articles: Gao, H., et al., Immunosensing with photo-immobilized immunoreagents on planar optical wave guides. Biosensors and Bioelectronics, 1995, Vol. 10, p. 317-328; Maisenholder, B., et al., A GaAs/AlGaAs-based refractometer platform for integrated optical sensing applications. Sensors and Actuators B, 1997, Vol. 38-39, p. 324-329; Kunz, R. E., Miniature integrated optical modules for chemical and biochemical sensing. Sensors and Actuators B, 1997, Vol. 38-39, p. 13-28; Dübendorfer, J. and R. E. Kunz, Reference pads for miniature integrated optical sensors. Sensors and Actuators B, 1997 Vol. 38-39, p. 116-121; Brecht, A. and G. Gauglitz, recent developments in optical transducers for chemical or biochemical applications. Sensors and Actuators B, 1997, Vol. 38-39, p. 1-7]. Interferometric optical biosensors have the intrinsic advantage of interferometric sensitivity, but are often characterized by large surface areas per element, long interaction lengths, or complicated resonance structures. They also can be susceptible to phase drift from thermal and mechanical effects. Current practice is to perform long time integrations (as in fluorescence detection) to achieve a significant signal. However, the long integration times place the measurement firmly in the range of 1/f noise (frequency=1/τ, where τ is the measurement time). Likewise, SPR measurement approaches (for example systems from Biacore) or resonant mirror approaches (for example systems from SRU Biosystems) are angle resolved or wavelength resolved, requiring detailed measurements that take long integration times.
While the abovementioned techniques have proven useful for producing and reading assay information within the chemical, biological, medical and diagnostic application industries, developing improved fabrication and reading techniques for planar arrays with significant improvement in performance over existing planar array technology is desirable.
One embodiment according to the present invention includes a method of probing a plurality of analyzer molecules distributed about a detection platform. The method includes contacting a test sample to the plurality of analyzer molecules, scanning the plurality of analyzer molecules at a rate relating to a carrier frequency signal, and detecting the presence or absence of a biological molecule based at least in part upon the presence or absence of a signal substantially at a sideband of the carrier frequency signal.
Another embodiment according to the present invention includes a molecule detection platform including a substrate and a plurality of targets positioned about the substrate. Specific analyzer molecules adapted to bind a specific analyte are immobilized about a first set of the targets. Nonspecific analyzer molecules are immobilized about a second set of the targets. The targets positioned about the substrate along at least a segment of a scanning pathway alternate between at least one of the first set and at least one of the second set.
A further embodiment according to the present invention includes a method including providing a substrate for supporting biological analyzer molecules. The substrate includes at least one scanning pathway. The scanning pathway including a plurality of scanning targets. The method further includes distributing specific biological analyzer molecules adapted to detect a specific target analyte about a first set of the targets which alternate in groups of at least one with a second set of the targets. The second set of the targets does not include the specific biological analyzer molecules.
Additional embodiments, aspects, and advantages of the present invention will be apparent from the following description.
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.
For the purposes of promoting an understanding of the principles of the invention, reference will now be made to the embodiments illustrated in the drawings and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations and further modifications in the illustrated device, and such further applications of the principles of the invention as illustrated therein being contemplated as would normally occur to one skilled in the art to which the invention relates.
With reference to
With reference to
Graph 2000 illustrates one example of frequency domain detection of the molecular, cellular, or particulate content of a liquid or air sample in which an analyte binds on or in a support material to produce a periodic, quasi-periodic or harmonic modulation of phase or amplitude of an electromagnetic wave that probes the support material. The periodic or quasi-periodic modulation can be in time or space, leading to a time-domain carrier frequency or a space-domain carrier frequency, by relative motion of the probe beam and support. The presence of the bound analyte appears as a modulation sideband of the carrier frequency. As shown in graph 2000, carrier sideband signals 2050 and 2070 indicate the presence of one or more target analytes bound to analyzer molecules distributed about a support material which is probed with an electromagnetic wave in a detection system. The detection system preferably includes a photodetector, or another detector responsive to electromagnetic waves, that outputs a current as described below by Equation 1:
Equation 1 has a harmonic decomposition described by Equation 2:
Equation 2 describes a DC sideband at ωm, a carrier band at ωc, and two carrier sidebands at ωc−ωm and ωc+ωm which correspond to DC sideband 2040, a carrier 2060, and sidebands 2050 and 2070 as shown in graph 2000. In Equations 1 and 2, t is time, i(t) is detector output current as a function of time, ωc is carrier angular frequency, ωm the modulation angular frequency, and A is the envelope amplitude. In further embodiments detector output could be a voltage, another electrical signal, an optical signal, or a magnetic signal, for example, or some combination of these and/or other outputs.
With reference to
Elements 3010 include specific analyzer molecules which selectively bind with a target analyte and elements 3020 include nonspecific analyzer molecules which do not selectively bind with a target analyte but may exhibit similar binding properties with respect to other molecules. In a preferred embodiment according to the present invention, elements 3010 include specific antibodies immobilized about their surfaces, for example, as a monolayer, fractional monolayer, partial monolayer, or near monolayer, and elements 3020 include similarly immobilized nonspecific antibodies. For example, if an assay is to be conducted to identify a particular mouse protein the specific antibody could be goat anti-mouse IgG (the antibody to the mouse protein produced by a goat) and the nonspecific antibody could be goat anti-rat IgG (the antibody to an analogous rat protein produced by a goat). The goat anti-mouse IgG will selectively bind the mouse protein while the goat anti-rat IgG will not bind with it or will have a substantially lesser binding affinity, however, both IgGs exhibit similar nonspecific background binding with molecules other than the target analyte. In additional embodiments the non-specific protein could be a non-IgG, for example, casein or bovine serum albumin (BSA). These proteins could be used to test general protein-protein background, and could be used to test for systematics that are common to both groups of immobilized molecules. In further embodiments the specific analyzer molecules could be a cDNA that is complimentary to the target DNA, and the non-specific group could be a statistically similar, but not identical, cDNA. Additional embodiments cal include specific and non-specific aptamers. A variety of other specific and nonspecific antibody pairs may also be used, including those exhibiting varying degrees of similarity in nonspecific background binding and those not exhibiting similar nonspecific background binding. Furthermore, combinations of specific and nonspecific analyzer molecules other than antibodies may also be used. Additionally, nonspecific analyzer molecules may be omitted entirely in which case elements 3020 would not include immobilized molecules. These alternative exemplary embodiments and others can be used in connection with the present embodiment and also in connection with the other embodiments including those described elsewhere herein.
Distribution of elements 3000 is one example of differential encoding or envelope modulation of bimolecular information. According to a preferred embodiment of the present invention, distribution of elements 3000 is on a bio-CD where elements 3010 and 3020 are interferometric microstructures formed on a surface of the bio-CD, and reading pathway 3004 is one of a number of a substantially concentric circular tracks. As described above, elements 3010 on the track are active (carrying a specific biological analyzer molecule) and elements 3020 are inactive (carrying nonspecific molecules, no molecules, or inert molecules that may be comparable in size with the analyzer molecule). In this 4 on/4 off format, the carrier frequency corresponds to the positioning of each individual one of elements 3010 and 3020, and the detection frequency corresponds to the repeat period of the unit cell UC which is every eight elements. Thus, the detection frequency is equal to one-eighth of the carrier frequency. At disk rotation speeds of 6000 rpm (100 Hz) and 1024 elements per track, the carrier frequency is approximately 100 kHz and the detection frequency is approximately 12.5 kHz. A wide variety of other bimolecular platforms, scanning rates, and element distributions including, for example, those described herein, are contemplated and can result in a variety of other carrier frequencies and detection frequencies.
According to a preferred embodiment of the present invention, an optical detection system including two phase-locked loops in series, with the front end referenced to the carrier frequency, and the back end referenced to the unit cell can be used to scan a bio-CD having distribution of elements 3000 with a laser. Differential encoding of distribution of elements 3000, for example as described above and elsewhere herein, can preferably reduce susceptibility to laser intensity drift or disk wobble by subtracting out these and other system drifts and biases, and can preferably directly subtract non-specific background binding, for example if the off region is printed with nonspecific antibody. One example of a detection system according to a preferred embodiment of the present invention can be found in U.S. Pat. No. 6,685,885 which is hereby incorporated by reference. This detection system could also be any other detection system responsive to electromagnetic waves including for example those described elsewhere herein.
According to a preferred embodiment of the present invention the detection system can utilize phase quadrature interferometric techniques. Examples of phase quadrature interferometric techniques include the micro-diffraction quadrature class (“MD-class”) and adaptive optic quadrature class (“AO-class”) as described in U.S. application Ser. No. 10/726,772 filed on Dec. 3, 2003 entitled “Adaptive Interferometric Multi-Analyte High-Speed Biosensor” (published on Aug. 26, 2004 as U.S. Pub. No. 2004/0166593), the contents of which are incorporated herein by reference. Other examples of phase quadrature interferometric techniques include the phase-contrast quadrature class (“PC-class”) as described in U.S. Provisional Patent Application No. 60/649,070, filed Feb. 1, 2005, entitled “Phase-Contrast Quadrature For Spinning Disk Interferometry And Immunological Assay”, U.S. Provisional Patent Application No. 60/755,177, filed Dec. 30, 2005, entitled “Phase-Contrast BioCD: High-Speed Immunoassays at Sub-Picogram Detection Levels”, and U.S. application Ser. No. 11/345,462 being filed the same day as the present application that claims priority to these two provisional applications and entitled “Method And Apparatus For Phase Contrast Quadrature Interferometric Detection Of An Immunoassay.” The disclosure of the utility application being filed on the same day as the present application is incorporated herein by reference. Additionally, further embodiments of the present invention include detection systems adapted to utilize surface plasmon resonance or SPR, fluorescence, resonance and other techniques in which high frequency modulation in time or space originates from analyte bound to a solid support with a spatial frequency that is scanned to produce a sideband indicating the presence of the analyte. Still other preferred embodiments of the present invention include detection platforms for use in these and other detection systems which include distributions of targets including analyzer molecules which produce sideband signals that depend upon modulation indicative of the presence of an analyte.
With reference to
Biosensor platform 4000 is one example of carrier suppression according to a preferred embodiment of the present invention. Elements 4060 and 4040 have a height illustrated by arrows HA and elements 4050 and 4070 have a height illustrated by arrows HB. Height HA is about λ/8 and height HB is about 3λ/8. Successive scanning of elements alternating between height HA and HB flips the phase quadratures detected for successive elements. This results in a modulation at about twice the amplitude as compared to a platform having interferometric elements with substantially uniform element heights. The carrier is suppressed by an approximately π phase difference between phase quadrature signals detected for successive elements. Carrier suppression may be useful in a variety of circumstances. In one example, where carrier side bands are weak relative to the carrier, carrier noise can impact detection. In another example where carrier sidebands overlap with the carrier, carrier noise can also impact detection. Carrier wave suppression can preferably increase the ratio of signal to noise. Complete carrier suppression or double sideband detection may be used to improve the signal to noise ratio of detection in these and other situations. Partial carrier suppression may also improve the signal to noise ratio of detection in these and other situations. Carrier wave suppression can also be accomplished in other manners, for example, fabrication of disk structures and reflectivities relative to beam width, through use of a clipper circuit that clips the high signal detected from a land of a detection platform, or through use of a filter, for example a band stop filter.
With reference to
The total reflected intensity is given by Equation 4:
Under the condition of Land: Φ=0, AL=A and Ar=0. Thus, intensity reflected by land is given by Equation 5:
IL=I0RL
Under the condition of Quadrature: Φ=π/2. Thus, the reflected intensity under a condition of quadrature is given by Equation 6:
where ai is the area fraction, and aL+ar=1. Conditions of balanced operation are given by Equations 7 and 8:
IQ=IL
RLaL2+Rrar2=RL
The solution of which are given in Equations 9 and 10:
For Equations 3-10, Ir is the total reflected intensity, IL is the intensity reflected by land, IO is the incident reflected intensity, IQ is the reflected intensity under a condition of quadrature, Eo is the reflected field, A is the total area, AL is area 5021, Ar is area 5011, aL is AL divided by the area of the beam footprint, aR is AL divided by the area of the element 5010 intersecting element 5020, RL is |rL|2, Rr is |rr|2 and Φ is the phase difference between reflected components of the laser. Thus, if the partially reflective substrate is silicon, for example, which has RL=32% and Rr=98%, then aL=51% and ar=49%.
With reference to
During scanning of platform 6000 by laser beam 6002 signal phase modulation depends only upon the binding differences between the specific and nonspecific analyzer molecules. For example, nonspecific binding that is common to both the types of analyzer molecules is not imparted onto the signal beam or has minimal impact on the signal beam. The detected signal is therefore independent of nonspecific binding. In this embodiment there is no signal detected at or about the carrier frequency and only the modulation caused by binding of the specific analyte and the specific analyzer molecule is detected. This is one example of differential encoding including carrier wave suppression and double sideband detection.
With reference to
During scanning of platform 7000 by a laser beam the phase of the carrier is periodically flipped by π for successive groups 7090 and 7091. The effect of the phase flipping of the carrier is that the carrier is suppressed in the power spectrum and the modulation due to binding of a specific analyzer molecule to the specific antibodies is detectable at carrier sidebands. This is one example of differential encoding including carrier wave suppression and double sideband detection.
According to a preferred embodiment modulated signals are detected within a detection bandwidth Δfd. Narrow bandwidths reject more noise, but the detection bandwidth should preferably not be smaller than the signal bandwidth, otherwise a part of the signal is rejected with the noise. The signal bandwidth is determined by the relationship described by Equation 11:
ΔωxΔτ=1
where Δωs=2πΔfs, Δfs is the signal bandwidth, and Δτ is the duration of either a contiguous part of the signal, or the duration of the signal detection measurement. In preferred embodiments utilizing bio-CDs, the carrier frequency, fcarrier, is set by the rotation frequency of the bio-CD, fdisk, and by the number of spokes, targets, or interferometric elements, N, around a specified circumference as described by Equation 12:
fcarrier=Nfdisk
The signal bandwidth Δfs is described by Equation 13:
The relative signal bandwidth Δfrel is described by Equation 14:
For a single continuous track around a circumference, the relative bandwidth Δfrel is described by Equation 14:
If a circumference is divided into S equal arcs of M spokes, the relative bandwidth increases by a factor of S as described by Equation 15:
Thus, for example, if N=1024, and S=16, the relative bandwidth is 0.25%. If fdisk=100 Hz, then fs=100 kHz, Δfs=16 Hz and Δfs rel=256 Hz. These relations suggest that S up to 128 segments or more is clearly a possible scenario for homogeneous bandwidths for which Δfs=2 kHz and Δfs rel=2%.
The foregoing example describes the case of homogeneous signal bandwidth. Signal bandwidths in practice are generally larger than the homogeneous bandwidths. These arise, for example, from frequency instability, which in the bio-CDs is from inhomogeneities in the fabricated or printed spokes. If the placement of the spokes is only accurate to 10 microns, then the bandwidth of the repetitive spoke pattern is approximately 4 kHz with a relative bandwidth of 4%. This inhomogeneous signal bandwidth sets the correct detection bandwidth for the bio-CDs. The number of segments can be increased to increase the homogeneous bandwidth until it is equal to the inhomogeneous bandwidth to the relationships described by Equations 16 and 17:
For detection bandwidth BW, this sets the maximum segment number according to Equation 18:
which for BW=3 kHz and fcarrier=100 kHz for N=1024, this sets the maximum S=136.
The ability to support segments suggests a disk array layout that segments the printed antibodies into wells. For N wells on a disk or S segments, the size of a well and its radial thickness are given by Equations 19 and 20:
where a is the area of a well, r is radius, dr is radial thickness of a well, θ is angular position, dθ is well arc length, A is the area of the annular region between radii R2 and R1, N is number of wells, S is the number of segments, R1 is the inner radius, and R2 is the outer radius.
With reference to
Bio-CD 8000 is one example of an equal area well layout according to the present invention. Other layouts are also contemplated, for example, a 512 well layout with S=16, T=32, and any other combination of sectors and tracks. According to a preferred embodiment layouts are used which bring the aspect ratio of arc length and radial thickness closer to unity which simplifies fabrication. Fabrication of this and other embodiments of the present invention can include particular features for various classes of bio-CDs. For example, a micro-diffraction bio-CD can have radial spokes fabricated from gold across the entire disk, and wells defined by hydrophobic dams. A pin plotter or ink-jet printer modified from biochip array printers can be used to deposit an equal amount of analyzer molecules into each well. Different antibodies can be deposited which then self-immobilize on thiolated gold. In another example gel printing can be used. In another example, for adaptive optical bio-CDs and phase constant bio-CDs, spokes can be printed as inert protein, dams can be put into place and antibody deposited into the wells by pin array plotters or protein spotters.
With reference to
where Λ is the spatial period, usually Λ=2w, where w is the beam waist. For a beam waist of 20 microns and Λ=40 microns, this gives the number of spokes as a function of radius C=3000 at r=20 mm and C=8000 at r=50 mm. The carrier frequencies are 300 kHz and 800 kHz, respectively.
For N wells, the area of each well is given by Equation 22:
a=rdθdr=A/N
The aspect ratio ar is set by the Equation 23:
rdθ=ardr
The radial widths and angular widths are given by Equation 24:
With reference to
where Λ is the spatial periodicity and νspatial is the spatial frequency.
During scanning targets 12000 are illuminated by a scanning footprint such as a laser spot. The scanning footprint could be, for example, focused laser spot vv which has a width wo less than spatial periodicity Λ (preferably wo<<Λ) and moves relative to the targets 12000 with a velocity in the direction indicated by arrow v. Under these scanning conditions the spatial frequency νspatial is converted into temporal frequency on the transmitted or reflected beam as described by Equation 26:
f=V·ν
where f is the carrier frequency of phase or amplitude modulation.
The scanning footprint could also be, for example, broad area laser spot z which has a width wo greater than spatial periodicity Λ (preferably wo>>Λ) and can be stationary or can move relative to the targets 12000 with a velocity V in the direction indicated by arrow v. When laser spot z is stationary and broadly illuminates the spatial frequency, then the spatial frequency leads to diffraction at specific angles as described by Equation 27:
where λ is the illumination wavelength, and Λ is the spatial period. When laser spot z moves over to targets 12000, or targets 12000 move with velocity V, then the diffracted orders acquire a phase modulation that is time-periodic.
The foregoing examples illustrate how spatial frequencies on a scanning platform, for example a chip or disk, can be converted into temporal frequencies in a laser scanning system, and how the two types of frequencies can be combined when a laser probes more than one target on the platform.
With reference to
Experimental demonstrations of several exemplary embodiments including carrier side band detection according to the present invention will now be described in connection with
Scanning the MD-class calibration disk produced signal 14030 which includes a series of alternating local minima 14031 and 14032 corresponding to and indicating the two spoke heights. The signal intensity difference between the alternating local minima 14031 and 14032 is illustrated by arrow 14040 and corresponds to a height difference of about 30 nm between alternating spokes. This height difference is representative of the height difference cause by certain target analytes to analyzer molecules. The signal level corresponding to the average spoke height of about 80 nm is indicated by dashed line 14050. The MD-class calibration disk thus provides a simulation of a differential encoding scheme whereby every other alternating spoke includes analyzer molecules that bind a target analyte and can be compared to a reference spoke. The fast relative comparison between the two types of spokes allows for significant noise reduction.
With reference to
With reference to
Graph 16000 shows 16030 the 1/f noise at DC and two DC sideband signals 16031 and 16032. A carrier frequency signal (not shown) is present at about 100 kHz. The presence of protein is detected as a 1/64 harmonic of the carrier frequency at about 1.6 kHz as shown by signal 16032 and also by signal 16031 at about −1.6 kHz. A second harmonic signal 16034 and 16033 is also present at 1/32 the carrier frequency and is caused by slight asymmetry in the deposition of the proteins. A comparison of protein track signal 16050 and signal 16060 of a control track containing no protein illustrates the strong effect of the protein in producing sideband signals with a 20:1 signal to noise ratio as indicated by arrow 16040.
With reference to
With reference to
With reference to
With reference to
With reference to
With reference to
With reference to
With reference to
With reference to
An exemplary procedure for sideband detection will now be described with reference to
While the examples illustrated and described above in connection with
Various embodiments according to the present invention can include a variety of biosensor platforms including those described above. For example, these platforms include bio-CDs such as micro-diffraction bio-CDs, adaptive-optical bio-CDs, phase-contrast bio-CDs, and others. Details relating to these various classes of bio-CDs can be found, for example, in the aforementioned patents and patent applications. These platforms further include bio-chips, immunological chips, gene chips, DNA arrays, platforms used in connection with fluorescence assays and other platforms and substrates supporting planar arrays including analyzer molecules including, for example, those described herein.
Various embodiments according to the present invention can include a variety of analyzer molecules useful in detecting the presence or absence of a variety of target analytes in a solution to be tested. For example, these analyzer molecules can include antibodies or immunoglobulins, antigens, DNA fragments, cDNA fragments, aptameres, peptides, proteins, and other molecules. Various embodiments according to the present invention can include combinations of one or more of the foregoing and other types of analyzer molecules known to a person of ordinary skill in the art arranged, for example, in a planar array.
Various embodiments according to the present invention can be used in connection with a variety of scanning and detection techniques. For example, such techniques include interferometry, including surface normal interferometry techniques, and preferably phase quadrature interferometry techniques where one detected optical mode differs in phase from another by about π/2 plus or minus about twenty percent or an odd integer multiple thereof, and/or self referencing interferometry techniques where a reference wave is generated locally with respect to a signal wave so that the reference and signal waves experience common aberrations and path length changes and thus maintain a constant relative phase without the need for active stabilization of different light paths, florescence techniques and platforms, resonance techniques and platforms, and other techniques and platforms.
As used herein terms relating to properties such as geometries, shapes, sizes, physical configurations, speeds, rates, frequencies, periods, amplitudes, include properties that are substantially or about the same or equal to the properties described unless explicitly indicated to the contrary.
While the invention has been illustrated and described in detail in the drawings and foregoing description, the same is to be considered as illustrative and not restrictive in character, it being understood that only preferred embodiments have been shown and described and that all changes and modifications that come within the spirit of the invention are desired to be protected.
This application is a divisional of U.S. patent application Ser. No. 11/345,566, filed Feb. 1, 2006 now abandoned, the complete disclosure of which is hereby expressly incorporated herein by this reference. This application also claims the benefit of U.S. Provisional Patent Application Ser. No. 60/648,724 filed Feb. 1, 2005, the complete disclosure of which is hereby expressly incorporated herein by this reference.
This invention was made with government support under grant reference number NSF ECS-0200424 awarded by the National Science Foundation. The Government has certain rights in the invention.
Number | Name | Date | Kind |
---|---|---|---|
3796495 | Laub | Mar 1974 | A |
4537861 | Elings et al. | Aug 1985 | A |
4741620 | Wickramasinghe | May 1988 | A |
4876208 | Gustafson et al. | Oct 1989 | A |
4899195 | Gotoh | Feb 1990 | A |
4975217 | Brown | Dec 1990 | A |
RE33581 | Nicoli et al. | Apr 1991 | E |
5122284 | Braynin et al. | Jun 1992 | A |
5155549 | Dhadwal | Oct 1992 | A |
5413939 | Gustafson et al. | May 1995 | A |
5478527 | Gustafson et al. | Dec 1995 | A |
5478750 | Bernstein et al. | Dec 1995 | A |
5494829 | Sandstrom et al. | Feb 1996 | A |
5497007 | Uritsky et al. | Mar 1996 | A |
5545531 | Rava et al. | Aug 1996 | A |
5581345 | Oki et al. | Dec 1996 | A |
5602377 | Beller et al. | Feb 1997 | A |
5621532 | Ooki et al. | Apr 1997 | A |
5629044 | Rubenchik | May 1997 | A |
5631171 | Sandstrom et al. | May 1997 | A |
5653939 | Hollis et al. | Aug 1997 | A |
5700046 | Van Doren et al. | Dec 1997 | A |
5717778 | Chu et al. | Feb 1998 | A |
5736257 | Conrad et al. | Apr 1998 | A |
5781649 | Brezoczky | Jul 1998 | A |
5786226 | Bocker et al. | Jul 1998 | A |
5837475 | Dorsel et al. | Nov 1998 | A |
5843767 | Beattie | Dec 1998 | A |
5844871 | Maezawa | Dec 1998 | A |
5874219 | Rava et al. | Feb 1999 | A |
5875029 | Jann et al. | Feb 1999 | A |
5883717 | DiMarzio et al. | Mar 1999 | A |
5892577 | Gordon | Apr 1999 | A |
5900935 | Klein et al. | May 1999 | A |
5922617 | Wang et al. | Jul 1999 | A |
5935785 | Reber et al. | Aug 1999 | A |
5945334 | Besemer et al. | Aug 1999 | A |
5945344 | Hayes et al. | Aug 1999 | A |
5955377 | Maul et al. | Sep 1999 | A |
5968728 | Perttunen et al. | Oct 1999 | A |
5999262 | Dobschal et al. | Dec 1999 | A |
6008892 | Kain et al. | Dec 1999 | A |
6030581 | Virtanen | Feb 2000 | A |
6048692 | Maracas et al. | Apr 2000 | A |
6060237 | Nygren et al. | May 2000 | A |
6071748 | Modlin et al. | Jun 2000 | A |
6099803 | Ackley | Aug 2000 | A |
6110748 | Reber et al. | Aug 2000 | A |
6121048 | Zaffaroni et al. | Sep 2000 | A |
6140044 | Besemer et al. | Oct 2000 | A |
6143247 | Sheppard | Nov 2000 | A |
6177990 | Kain et al. | Jan 2001 | B1 |
6221579 | Everhart et al. | Apr 2001 | B1 |
6238869 | Kris et al. | May 2001 | B1 |
6248539 | Ghadiri et al. | Jun 2001 | B1 |
6249593 | Chu et al. | Jun 2001 | B1 |
6256088 | Gordon | Jul 2001 | B1 |
6271924 | Ngoi et al. | Aug 2001 | B1 |
6287783 | Maynard et al. | Sep 2001 | B1 |
6287850 | Besemer et al. | Sep 2001 | B1 |
6312901 | Virtanen | Nov 2001 | B2 |
6312961 | Voirin et al. | Nov 2001 | B1 |
6319468 | Sheppard, Jr. et al. | Nov 2001 | B1 |
6319469 | Mian et al. | Nov 2001 | B1 |
6320665 | Ngoi et al. | Nov 2001 | B1 |
6327031 | Gordon | Dec 2001 | B1 |
6339473 | Gordon | Jan 2002 | B1 |
6342349 | Virtanen | Jan 2002 | B1 |
6342395 | Hammock et al. | Jan 2002 | B1 |
6345115 | Ramm et al. | Feb 2002 | B1 |
6350413 | Reichert et al. | Feb 2002 | B1 |
6355429 | Nygren et al. | Mar 2002 | B1 |
6368795 | Hefti | Apr 2002 | B1 |
6376258 | Hefti | Apr 2002 | B2 |
6381025 | Bornhop et al. | Apr 2002 | B1 |
6387331 | Hunter | May 2002 | B1 |
6395558 | Duveneck et al. | May 2002 | B1 |
6395562 | Hammock et al. | May 2002 | B1 |
6399365 | Besemer et al. | Jun 2002 | B2 |
6403957 | Fodor et al. | Jun 2002 | B1 |
6416642 | Alajoki et al. | Jul 2002 | B1 |
6469787 | Meyer et al. | Oct 2002 | B1 |
6476907 | Gordon | Nov 2002 | B1 |
6483585 | Yang | Nov 2002 | B1 |
6483588 | Graefe et al. | Nov 2002 | B1 |
6496267 | Takaoka | Dec 2002 | B1 |
6496309 | Bliton et al. | Dec 2002 | B1 |
6504618 | Morath et al. | Jan 2003 | B2 |
6518056 | Schembri et al. | Feb 2003 | B2 |
6551817 | Besemer et al. | Apr 2003 | B2 |
6566069 | Virtanen | May 2003 | B2 |
6584217 | Lawless et al. | Jun 2003 | B1 |
6591196 | Yakhini et al. | Jul 2003 | B1 |
6596483 | Choong et al. | Jul 2003 | B1 |
6602702 | McDevitt et al. | Aug 2003 | B1 |
6623696 | Kim et al. | Sep 2003 | B1 |
6624896 | Neal et al. | Sep 2003 | B1 |
6649403 | McDevitt | Nov 2003 | B1 |
6653152 | Challener | Nov 2003 | B2 |
6656428 | Clark et al. | Dec 2003 | B1 |
6685885 | Nolte et al. | Feb 2004 | B2 |
6687008 | Peale et al. | Feb 2004 | B1 |
6709869 | Mian et al. | Mar 2004 | B2 |
6720177 | Ghadiri et al. | Apr 2004 | B2 |
6733977 | Besemer et al. | May 2004 | B2 |
6734000 | Bhatia | May 2004 | B2 |
6737238 | Suzuki | May 2004 | B2 |
6743633 | Hunter | Jun 2004 | B1 |
6760298 | Worthington et al. | Jul 2004 | B2 |
6766817 | da Silva | Jul 2004 | B2 |
6770447 | Maynard et al. | Aug 2004 | B2 |
6783938 | Nygren et al. | Aug 2004 | B2 |
6787110 | Tiefenthaler | Sep 2004 | B2 |
6791677 | Kawai et al. | Sep 2004 | B2 |
6803999 | Gordon | Oct 2004 | B1 |
6806963 | Walti et al. | Oct 2004 | B1 |
6819432 | Pepper et al. | Nov 2004 | B2 |
6836338 | Opsal et al. | Dec 2004 | B2 |
6844965 | Engelhardt | Jan 2005 | B1 |
6847452 | Hill | Jan 2005 | B2 |
6878555 | Andersson et al. | Apr 2005 | B2 |
6897965 | Ghadiri et al. | May 2005 | B2 |
6917421 | Wihl et al. | Jul 2005 | B1 |
6917432 | Hill et al. | Jul 2005 | B2 |
6918404 | da Silva | Jul 2005 | B2 |
6937323 | Worthington et al. | Aug 2005 | B2 |
6955878 | Kambara et al. | Oct 2005 | B2 |
6958131 | Tiefenthaler | Oct 2005 | B2 |
6980299 | de Boer | Dec 2005 | B1 |
6980677 | Niles et al. | Dec 2005 | B2 |
6987569 | Hill | Jan 2006 | B2 |
6990221 | Shams | Jan 2006 | B2 |
6992769 | Gordon | Jan 2006 | B2 |
6995845 | Worthington | Feb 2006 | B2 |
7006927 | Yakhini et al. | Feb 2006 | B2 |
7008794 | Goh et al. | Mar 2006 | B2 |
7012249 | Krutchinsky et al. | Mar 2006 | B2 |
7014815 | Worthington et al. | Mar 2006 | B1 |
7026131 | Hurt et al. | Apr 2006 | B2 |
7027163 | Angeley | Apr 2006 | B2 |
7031508 | Lawless et al. | Apr 2006 | B2 |
7033747 | Gordon | Apr 2006 | B2 |
7042570 | Sailor | May 2006 | B2 |
7061594 | Worthington et al. | Jun 2006 | B2 |
7066586 | da Silva | Jun 2006 | B2 |
7070987 | Cunningham et al. | Jul 2006 | B2 |
7077996 | Randall et al. | Jul 2006 | B2 |
7083920 | Werner et al. | Aug 2006 | B2 |
7087203 | Gordon et al. | Aug 2006 | B2 |
7088650 | Worthington et al. | Aug 2006 | B1 |
7091034 | Virtanen | Aug 2006 | B2 |
7091049 | Boga et al. | Aug 2006 | B2 |
7094595 | Cunningham et al. | Aug 2006 | B2 |
7094609 | Demers | Aug 2006 | B2 |
7098041 | Kaylor et al. | Aug 2006 | B2 |
7102752 | Kaylor et al. | Sep 2006 | B2 |
7106513 | Moon et al. | Sep 2006 | B2 |
7110094 | Gordon | Sep 2006 | B2 |
7110345 | Worthington et al. | Sep 2006 | B2 |
7118855 | Cohen et al. | Oct 2006 | B2 |
7141378 | Miller et al. | Nov 2006 | B2 |
7141416 | Krutzik | Nov 2006 | B2 |
7145645 | Blumenfeld et al. | Dec 2006 | B2 |
7148970 | de Boer | Dec 2006 | B2 |
7200088 | Worthington et al. | Apr 2007 | B2 |
7221632 | Worthington et al. | May 2007 | B2 |
7312046 | Chin | Dec 2007 | B2 |
7318903 | Link | Jan 2008 | B2 |
20010055812 | Mian et al. | Dec 2001 | A1 |
20020001546 | Hunter et al. | Jan 2002 | A1 |
20020008871 | Poustka et al. | Jan 2002 | A1 |
20020045276 | Yguerabide et al. | Apr 2002 | A1 |
20020051973 | Delenstarr et al. | May 2002 | A1 |
20020058242 | Demers | May 2002 | A1 |
20020085202 | Gordon | Jul 2002 | A1 |
20020097658 | Worthington et al. | Jul 2002 | A1 |
20020106661 | Virtanen et al. | Aug 2002 | A1 |
20020127565 | Cunningham et al. | Sep 2002 | A1 |
20020135754 | Gordon | Sep 2002 | A1 |
20020151043 | Gordon | Oct 2002 | A1 |
20020177144 | Remacle et al. | Nov 2002 | A1 |
20020192664 | Nygren et al. | Dec 2002 | A1 |
20030026735 | Nolte et al. | Feb 2003 | A1 |
20030035352 | Worthington | Feb 2003 | A1 |
20030054376 | Mullis et al. | Mar 2003 | A1 |
20030112446 | Miller et al. | Jun 2003 | A1 |
20030133640 | Tiefenthaler | Jul 2003 | A1 |
20030134330 | Ravkin et al. | Jul 2003 | A1 |
20040002085 | Schembri et al. | Jan 2004 | A1 |
20040078337 | King et al. | Apr 2004 | A1 |
20040086929 | Weide et al. | May 2004 | A1 |
20040106130 | Besemer et al. | Jun 2004 | A1 |
20040132172 | Cunningham et al. | Jul 2004 | A1 |
20040150829 | Koch et al. | Aug 2004 | A1 |
20040155309 | Sorin | Aug 2004 | A1 |
20040166525 | Besemer et al. | Aug 2004 | A1 |
20040166593 | Nolte et al. | Aug 2004 | A1 |
20040223881 | Cunningham et al. | Nov 2004 | A1 |
20040229254 | Clair | Nov 2004 | A1 |
20040247486 | Tiefenthaler | Dec 2004 | A1 |
20040258927 | Conzone et al. | Dec 2004 | A1 |
20050002827 | McIntyre et al. | Jan 2005 | A1 |
20050003459 | Krutzik | Jan 2005 | A1 |
20050019901 | Matveeva et al. | Jan 2005 | A1 |
20050042628 | Rava et al. | Feb 2005 | A1 |
20050084422 | Kido et al. | Apr 2005 | A1 |
20050084895 | Besemer et al. | Apr 2005 | A1 |
20050106746 | Shinn et al. | May 2005 | A1 |
20050123907 | Rava et al. | Jun 2005 | A1 |
20050131745 | Keller et al. | Jun 2005 | A1 |
20050158819 | Besemer et al. | Jul 2005 | A1 |
20050176058 | Zaffaroni et al. | Aug 2005 | A1 |
20050191630 | Besemer et al. | Sep 2005 | A1 |
20050214950 | Roeder et al. | Sep 2005 | A1 |
20050226769 | Shiga | Oct 2005 | A1 |
20050248754 | Wang et al. | Nov 2005 | A1 |
20050254062 | Tan et al. | Nov 2005 | A1 |
20050259260 | Wakita | Nov 2005 | A1 |
20060040380 | Besemer et al. | Feb 2006 | A1 |
20060078935 | Werner et al. | Apr 2006 | A1 |
20060204399 | Freeman et al. | Sep 2006 | A1 |
20060210449 | Zoval et al. | Sep 2006 | A1 |
20060223172 | Bedingham et al. | Oct 2006 | A1 |
20060234267 | Besemer et al. | Oct 2006 | A1 |
20060256350 | Nolte et al. | Nov 2006 | A1 |
20060256676 | Nolte et al. | Nov 2006 | A1 |
20060257939 | Demers | Nov 2006 | A1 |
20060269450 | Kim et al. | Nov 2006 | A1 |
20060270064 | Gordon et al. | Nov 2006 | A1 |
20070003436 | Nolte et al. | Jan 2007 | A1 |
20070003925 | Nolte et al. | Jan 2007 | A1 |
20070003979 | Worthington | Jan 2007 | A1 |
20070023643 | Nolte et al. | Feb 2007 | A1 |
20070070848 | Worthington et al. | Mar 2007 | A1 |
20070077599 | Krutzik | Apr 2007 | A1 |
20070077605 | Hurt et al. | Apr 2007 | A1 |
20070108465 | Pacholski | May 2007 | A1 |
Number | Date | Country |
---|---|---|
1189062 | Mar 2002 | EP |
1424549 | Jun 2004 | EP |
WO 9104489 | Apr 1991 | WO |
WO 9104491 | Apr 1991 | WO |
WO 9113353 | Sep 1991 | WO |
WO 9214136 | Aug 1992 | WO |
WO 9403774 | Feb 1994 | WO |
WO 9837238 | Feb 1998 | WO |
WO 0000265 | Jan 2000 | WO |
WO 0039584 | Jul 2000 | WO |
WO 0111310 | Feb 2001 | WO |
WO 0144441 | Jun 2001 | WO |
WO 03014711 | Feb 2003 | WO |
WO 2006042746 | Apr 2006 | WO |
WO 2006075797 | Jul 2006 | WO |
Number | Date | Country | |
---|---|---|---|
20090263913 A1 | Oct 2009 | US |
Number | Date | Country | |
---|---|---|---|
60648724 | Feb 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11345566 | Feb 2006 | US |
Child | 12466943 | US |